CN1452482A - 含有胆碱和琥珀酸用于治疗胰岛素抵抗和糖尿病的协同组成物 - Google Patents

含有胆碱和琥珀酸用于治疗胰岛素抵抗和糖尿病的协同组成物 Download PDF

Info

Publication number
CN1452482A
CN1452482A CN00819413A CN00819413A CN1452482A CN 1452482 A CN1452482 A CN 1452482A CN 00819413 A CN00819413 A CN 00819413A CN 00819413 A CN00819413 A CN 00819413A CN 1452482 A CN1452482 A CN 1452482A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
succinic acid
choline
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00819413A
Other languages
English (en)
Chinese (zh)
Inventor
帕密特金·伊戈尔·阿那托列维奇
卡列索瓦·奥尔加·伊夫吉涅芙娜
马卡诺娃·塔奇亚娜·裘列娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1452482A publication Critical patent/CN1452482A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN00819413A 2000-04-10 2000-04-10 含有胆碱和琥珀酸用于治疗胰岛素抵抗和糖尿病的协同组成物 Pending CN1452482A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2000/000122 WO2001076583A1 (en) 2000-04-10 2000-04-10 Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes

Publications (1)

Publication Number Publication Date
CN1452482A true CN1452482A (zh) 2003-10-29

Family

ID=20129496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00819413A Pending CN1452482A (zh) 2000-04-10 2000-04-10 含有胆碱和琥珀酸用于治疗胰岛素抵抗和糖尿病的协同组成物

Country Status (8)

Country Link
EP (1) EP1272171A1 (enExample)
JP (1) JP3944393B2 (enExample)
KR (1) KR20020089444A (enExample)
CN (1) CN1452482A (enExample)
AU (1) AU2000263274A1 (enExample)
BR (1) BR0017206A (enExample)
CA (1) CA2404864A1 (enExample)
WO (1) WO2001076583A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102223883B (zh) * 2008-11-26 2013-07-10 伊戈尔·安那托利维奇·波米特金 用于治疗抑郁症、焦虑症、精神分裂症、睡眠障碍和癫痫症的琥珀酸的胆碱盐
CN107456449A (zh) * 2016-12-09 2017-12-12 杨远志 一种组合物及其在增加肌肉耐力中的应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112773A1 (en) * 2003-04-24 2004-12-29 Shin-Jen Shiao Pharmaceutical compositions used for immune disease treatment and improvement
CN101801368B (zh) * 2007-08-02 2012-06-13 布达生物制药有限公司 包含琥珀酸的胆碱盐的用于鼻内给药的药物组合物
US8314080B2 (en) 2010-04-06 2012-11-20 Kuwait University Method of treating type I diabetes
WO2024231663A1 (en) 2023-05-05 2024-11-14 Mitocholine Ltd Method of synthesis
WO2025163212A2 (en) 2024-08-09 2025-08-07 Jantar Gmbh Succinic acid or a pharmaceutically acceptable salt thereof for use in the treatment of chronic rhinosinusitis
WO2025120626A2 (en) 2025-04-14 2025-06-12 Mitocholine Ltd Synthetic method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6346669D0 (pt) * 1962-02-12 1973-06-14 Squibb & Sons Inc Processo de preparacao de uma composicao farmaceutica estavel de sais de esteres de colina
JPS61171417A (ja) * 1985-01-23 1986-08-02 Wakunaga Seiyaku Kk 抗糖尿病剤
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
JPH03169498A (ja) * 1989-11-28 1991-07-23 Yotsukaichi Gosei Kk 水溶性はんだフラックス
JPH0586319A (ja) * 1991-09-27 1993-04-06 Pentel Kk 水性インキ組成物
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
DE69917809T2 (de) * 1999-03-01 2004-11-04 Verteletsky, Pavel Vasilievich Verwendung von Bernsteinsäure oder deren Salze zur Behandlung von Insulinresistenz
CA2362116A1 (en) * 1999-04-05 2000-10-12 Igor Anatolievich Pomytkin Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102223883B (zh) * 2008-11-26 2013-07-10 伊戈尔·安那托利维奇·波米特金 用于治疗抑郁症、焦虑症、精神分裂症、睡眠障碍和癫痫症的琥珀酸的胆碱盐
CN107456449A (zh) * 2016-12-09 2017-12-12 杨远志 一种组合物及其在增加肌肉耐力中的应用

Also Published As

Publication number Publication date
BR0017206A (pt) 2003-01-14
KR20020089444A (ko) 2002-11-29
CA2404864A1 (en) 2001-10-18
AU2000263274A1 (en) 2001-10-23
WO2001076583A1 (en) 2001-10-18
EP1272171A1 (en) 2003-01-08
JP3944393B2 (ja) 2007-07-11
JP2004506605A (ja) 2004-03-04

Similar Documents

Publication Publication Date Title
CN1138539C (zh) 用于降低神经酰胺水平的碱性氨基酸和衍生物的应用
CN1452482A (zh) 含有胆碱和琥珀酸用于治疗胰岛素抵抗和糖尿病的协同组成物
JP2012515801A (ja) 糖尿病及び肥満症を治療するためのプテロシン化合物の使用
CN104105482B (zh) 红细胞生成素产生促进剂
CN1165314C (zh) 聚乳酸混合物在制备糖尿病治疗剂中的用途
EP1014808B1 (en) Fatty acids as a diet supplement
EP4331583A1 (en) Blood carnitine-increasing agent
EP2992888B1 (en) Use of pentacyclic triterpenoid saponin compound from szechuan melandium root for preparing hypoglycemic drug
US6521665B1 (en) Method of treating insulin resistance
CN1358092A (zh) 含有西布曲明和奥利司他的药物组合物
EP1399142A1 (en) Use of acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
CA3104916C (en) Pharmaceutical composition for preventing diabetes and use thereof
KR20210015883A (ko) 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산
US12502371B2 (en) Drug for treating and preventing dementia
WO2023163992A1 (en) Modulation of human breast milk composition
CN110575447A (zh) 一种用于防治糖尿病的药物组合物及其用途
JPH04198134A (ja) 老人性痴呆症の治療・予防剤
CN1976696A (zh) 用于预防或治疗脂质代谢异常的医药组合物
CN117653642A (zh) 格列本脲促进nad+水平的用途
WO2025152110A1 (zh) 用于阿尔兹海默症治疗的联合用药及其药物组合物
CN102743370B (zh) 双醋瑞因的用途
CN1741798A (zh) 预防或治疗子宫内生长迟缓和妊娠毒血症的药物
WO2000028944A2 (en) Use of succinic acid or salts thereof and method of treating insulin resistance
HK1031174B (en) Compositions and methods for treating diabetes
ZA200605461B (en) Compositions and methods for treating diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication